Literature DB >> 16919418

GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology.

Sahar Al-Mahdawi1, Ricardo Mouro Pinto, Dhaval Varshney, Lorraine Lawrence, Margaret B Lowrie, Sian Hughes, Zoe Webster, Julian Blake, J Mark Cooper, Rosalind King, Mark A Pook.   

Abstract

Friedreich ataxia (FRDA) is a neurodegenerative disorder caused by an unstable GAA repeat expansion mutation within intron 1 of the FXN gene. However, the origins of the GAA repeat expansion, its unstable dynamics within different cells and tissues, and its effects on frataxin expression are not yet completely understood. Therefore, we have chosen to generate representative FRDA mouse models by using the human FXN GAA repeat expansion itself as the genetically modified mutation. We have previously reported the establishment of two lines of human FXN YAC transgenic mice that contain unstable GAA repeat expansions within the appropriate genomic context. We now describe the generation of FRDA mouse models by crossbreeding of both lines of human FXN YAC transgenic mice with heterozygous Fxn knockout mice. The resultant FRDA mice that express only human-derived frataxin show comparatively reduced levels of frataxin mRNA and protein expression, decreased aconitase activity, and oxidative stress, leading to progressive neurodegenerative and cardiac pathological phenotypes. Coordination deficits are present, as measured by accelerating rotarod analysis, together with a progressive decrease in locomotor activity and increase in weight. Large vacuoles are detected within neurons of the dorsal root ganglia (DRG), predominantly within the lumbar regions in 6-month-old mice, but spreading to the cervical regions after 1 year of age. Secondary demyelination of large axons is also detected within the lumbar roots of older mice. Lipofuscin deposition is increased in both DRG neurons and cardiomyocytes, and iron deposition is detected in cardiomyocytes after 1 year of age. These mice represent the first GAA repeat expansion-based FRDA mouse models that exhibit progressive FRDA-like pathology and thus will be of use in testing potential therapeutic strategies, particularly GAA repeat-based strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16919418      PMCID: PMC2842930          DOI: 10.1016/j.ygeno.2006.06.015

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  42 in total

1.  Atypical Friedreich ataxia with a very late onset and an unusual limited GAA repeat.

Authors:  S Sorbi; P Forleo; E Cellini; S Piacentini; A Serio; B Guarnieri; C Petruzzi
Journal:  Arch Neurol       Date:  2000-09

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  The GAA*TTC triplet repeat expanded in Friedreich's ataxia impedes transcription elongation by T7 RNA polymerase in a length and supercoil dependent manner.

Authors:  E Grabczyk; K Usdin
Journal:  Nucleic Acids Res       Date:  2000-07-15       Impact factor: 16.971

4.  Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia.

Authors:  J L Bradley; J C Blake; S Chamberlain; P K Thomas; J M Cooper; A H Schapira
Journal:  Hum Mol Genet       Date:  2000-01-22       Impact factor: 6.150

5.  Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits.

Authors:  H Puccio; D Simon; M Cossée; P Criqui-Filipe; F Tiziano; J Melki; C Hindelang; R Matyas; P Rustin; M Koenig
Journal:  Nat Genet       Date:  2001-02       Impact factor: 38.330

6.  Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity.

Authors:  Anne-Laure Bulteau; Heather A O'Neill; Mary Claire Kennedy; Masao Ikeda-Saito; Grazia Isaya; Luke I Szweda
Journal:  Science       Date:  2004-07-09       Impact factor: 47.728

7.  GAA repeat instability in Friedreich ataxia YAC transgenic mice.

Authors:  Sahar Al-Mahdawi; Ricardo Mouro Pinto; Piers Ruddle; Christopher Carroll; Zoe Webster; Mark Pook
Journal:  Genomics       Date:  2004-08       Impact factor: 5.736

8.  Frataxin-mediated iron delivery to ferrochelatase in the final step of heme biosynthesis.

Authors:  Taejin Yoon; J A Cowan
Journal:  J Biol Chem       Date:  2004-04-27       Impact factor: 5.157

9.  The relationship between plasma triglycerides, cholesterol, total lipids and lipid peroxidation products during human atherosclerosis.

Authors:  A Ledwozyw; J Michalak; A Stepień; A Kadziołka
Journal:  Clin Chim Acta       Date:  1986-03-28       Impact factor: 3.786

10.  Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion.

Authors:  V Campuzano; L Montermini; M D Moltò; L Pianese; M Cossée; F Cavalcanti; E Monros; F Rodius; F Duclos; A Monticelli; F Zara; J Cañizares; H Koutnikova; S I Bidichandani; C Gellera; A Brice; P Trouillas; G De Michele; A Filla; R De Frutos; F Palau; P I Patel; S Di Donato; J L Mandel; S Cocozza; M Koenig; M Pandolfo
Journal:  Science       Date:  1996-03-08       Impact factor: 47.728

View more
  112 in total

1.  HSC20 interacts with frataxin and is involved in iron-sulfur cluster biogenesis and iron homeostasis.

Authors:  Yuxi Shan; Gino Cortopassi
Journal:  Hum Mol Genet       Date:  2011-12-13       Impact factor: 6.150

Review 2.  Advancements in the pathophysiology of Friedreich's Ataxia and new prospects for treatments.

Authors:  Ngolela E Babady; Nadege Carelle; Robert D Wells; Tracey A Rouault; Michio Hirano; David R Lynch; Martin B Delatycki; Robert B Wilson; Grazia Isaya; Hélène Puccio
Journal:  Mol Genet Metab       Date:  2007-06-26       Impact factor: 4.797

3.  Rapid and Complete Reversal of Sensory Ataxia by Gene Therapy in a Novel Model of Friedreich Ataxia.

Authors:  Françoise Piguet; Charline de Montigny; Nadège Vaucamps; Laurence Reutenauer; Aurélie Eisenmann; Hélène Puccio
Journal:  Mol Ther       Date:  2018-05-28       Impact factor: 11.454

Review 4.  Friedreich's ataxia: pathology, pathogenesis, and molecular genetics.

Authors:  Arnulf H Koeppen
Journal:  J Neurol Sci       Date:  2011-04-15       Impact factor: 3.181

5.  Oligodendroglial differentiation induces mitochondrial genes and inhibition of mitochondrial function represses oligodendroglial differentiation.

Authors:  Robert Schoenfeld; Alice Wong; Jillian Silva; Ming Li; Aki Itoh; Makoto Horiuchi; Takayuki Itoh; David Pleasure; Gino Cortopassi
Journal:  Mitochondrion       Date:  2009-12-22       Impact factor: 4.160

6.  Neurobehavioral deficits in the KIKO mouse model of Friedreich's ataxia.

Authors:  Marissa Z McMackin; Chelsea K Henderson; Gino A Cortopassi
Journal:  Behav Brain Res       Date:  2016-08-26       Impact factor: 3.332

Review 7.  Therapeutic strategies in Friedreich's ataxia.

Authors:  Timothy E Richardson; Heather N Kelly; Amanda E Yu; James W Simpkins
Journal:  Brain Res       Date:  2013-04-13       Impact factor: 3.252

Review 8.  Small molecules affecting transcription in Friedreich ataxia.

Authors:  Joel M Gottesfeld
Journal:  Pharmacol Ther       Date:  2007-08-09       Impact factor: 12.310

Review 9.  Mitochondrial Diseases Part II: Mouse models of OXPHOS deficiencies caused by defects in regulatory factors and other components required for mitochondrial function.

Authors:  Luisa Iommarini; Susana Peralta; Alessandra Torraco; Francisca Diaz
Journal:  Mitochondrion       Date:  2015-01-29       Impact factor: 4.160

10.  Limitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screen.

Authors:  Nadège Calmels; Hervé Seznec; Pascal Villa; Laurence Reutenauer; Marcel Hibert; Jacques Haiech; Pierre Rustin; Michel Koenig; Hélène Puccio
Journal:  BMC Neurol       Date:  2009-08-24       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.